{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:03:14Z","timestamp":1749873794024,"version":"3.41.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rapid remission has been shown to be beneficial in patients with early rheumatoid arthritis (RA). This study assessed the association of rapid and sustained remission with long-term clinician- and patient-reported outcomes (CRO\/PROs) in patients treated with b\/tsDMARDs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This post hoc analysis used pooled data on patients with moderately-to-severely active RA receiving upadacitinib or adalimumab from the SELECT-COMPARE trial (NCT02629159) and its open-label long-term extension (up to 5 years). This study assessed the effect of achieving rapid remission, time to remission, and time in sustained remission on CRO\/PROs. Rapid remission was defined as a Disease Activity Score 28 with C-reactive protein (DAS28-CRP)\u2009&lt;\u20092.6 after 12 weeks\u2019 treatment. The outcomes of interest included a variety of PROs, such as pain, fatigue, quality of life, and CROs (28 swollen\/tender joint counts). Where available, outcomes were assessed for up to 5 years; mean change in outcomes, as well as adjusted odds ratios (aOR) of achieving minimal clinically important differences (MCIDs) or normative values. Multivariate regression analyses were conducted adjusting for baseline covariates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 28% of patients (n\/<jats:italic>N<\/jats:italic>\u2009=\u2009247\/865; mean disease duration: 8.2\u2009\u00b1\u20097.8 years) achieved rapid remission. Rapid remission was associated with significantly greater improvements from baseline in all outcomes at Week 26 and significantly greater odds of achieving MCIDs (aOR range: 2.2\u20135.6) or normative values (aOR range: 1.6\u20139.8) in most PROs, including pain, fatigue, and physical functioning, over the variable 5-year follow-up; significantly lower swollen\/tender joint counts were also observed. Time to achieve remission was associated with better outcomes: for every month delay in achieving remission, likelihood of achieving MCIDs or normative values decreased, on average, by 13%. Increasing time spent in sustained remission was associated with long-term improvement in CRO\/PROs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Remission is a key outcome in RA; this study showed that achieving rapid remission, as well as reducing time to achieving remission, was associated with less pain and fatigue, and better physical functioning and quality of life over 5 years. Similarly, increasing time spent in sustained remission correlated with sustained improvement in CRO\/PROs. Striving for rapid, sustained remission leads to long-term benefits.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13075-025-03580-1","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:29:45Z","timestamp":1749788985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study"],"prefix":"10.1186","volume":"27","author":[{"given":"Laure","family":"Gossec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Kadakia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siran","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Strengholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"10","key":"3580_CR1","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","volume":"5","author":"GBDRA Collaborators","year":"2023","unstructured":"Collaborators GBDRA. Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2023;5(10):e594\u2013610.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"3580_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123\u201330.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3580_CR3","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar4491","volume":"16","author":"H Radner","year":"2014","unstructured":"Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16(1):R56.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3580_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12325-021-01946-w","volume":"39","author":"AJ Ostor","year":"2022","unstructured":"Ostor AJ, Sawant R, Qi CZ, Wu A, Nagy O, Betts KA. Value of remission in patients with rheumatoid arthritis: a targeted review. Adv Ther. 2022;39(1):75\u201393.","journal-title":"Adv Ther"},{"issue":"1","key":"3580_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3580_CR6","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s10067-019-04600-7","volume":"38","author":"PM Ten Klooster","year":"2019","unstructured":"Ten Klooster PM, Oude Voshaar MAH, Fakhouri W, de la Torre I, Nicolay C, van de Laar M. Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy. Clin Rheumatol. 2019;38(10):2727\u201336.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"3580_CR7","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar3027","volume":"12","author":"LG Schipper","year":"2010","unstructured":"Schipper LG, Fransen J, den Broeder AA, Van Riel PL. Time to achieve remission determines time to be in remission. Arthritis Res Ther. 2010;12(3):R97.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3580_CR8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3899\/jrheum.100935","volume":"38","author":"EC Keystone","year":"2011","unstructured":"Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011;38(6):990\u20136.","journal-title":"J Rheumatol"},{"issue":"10","key":"3580_CR9","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56(10):3226\u201335.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3580_CR10","doi-asserted-by":"publisher","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","volume":"8","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022;8(1):e002012.","journal-title":"RMD Open"},{"issue":"11","key":"3580_CR11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3580_CR12","doi-asserted-by":"publisher","first-page":"e003860","DOI":"10.1136\/rmdopen-2023-003860","volume":"10","author":"SVJ Snoeck Henkemans","year":"2024","unstructured":"Snoeck Henkemans SVJ, Vis M, Looijen AEM, van der Helm-van Mil AHM, de Jong PHP. Patient-reported outcomes and radiographic progression in patients with rheumatoid arthritis in sustained remission versus low disease activity. RMD Open. 2024;10(1):e003860.","journal-title":"RMD Open"},{"issue":"10","key":"3580_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1759720X17720366","volume":"9","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9(10):249\u201362.","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03580-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:29:45Z","timestamp":1749788985000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03580-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3580"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03580-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used data from the phase 3 trial SELECT-COMPARE, which was conducted as per the International Conference on Harmonisation guidelines, the Declaration of Helsinki, and any other applicable regulations. Study-related documents were approved by the US Central Institutional Review Board (Quorum #31009) and other local institutional ethics committees and review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Laure Gossec has received grants or contracts from AbbVie, Biogen, Lilly, Novartis, and UCB; consulting fees from AbbVie, BMS, Celltrion, Janssen, Novartis, Pfizer, and UCB; honoraria for lectures from AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, MSD, Novartis, Pfizer, Stada, and UCB; support for attending meetings and\/or travel from Biogen, MSD, and Pfizer; medical writing support from AbbVie, Amgen, Janssen, Pfizer, and UCB; and serves as the EULAR treasurer. Jayesh Patel, Aditi Kadakia, Siran Fang, and Yi Peng are employees of AbbVie and may own stock, stock options, or patents. Sander Strengholt is a former employee of AbbVie and may own stock, stock options, or patents. Peter C. Taylor reports grants\/contracts from Galapagos to University of Oxford; consulting fees from AbbVie, Biogen, Fresenius, Takeda, Galapagos, Gilead, Janssen, Lilly, Nordic Pharma, Pfizer, UCB, and Acelyrin Inc.; and participation on a Data Safety Monitoring Board\/Advisory Board for Immunovant, Sanofi, and Moonlake. Andrew \u00d6st\u00f6r has been a consultant, served on Advisory boards, and has undertaken clinical trials for AbbVie, Janssen, Lilly, Novartis, Pfizer, and GSK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}